WELL’s subsidiary OceanMD has signed a $38.5 million contract with British Columbia’s Provincial Health Services Authority to provide an array of digital services, such as eReferrals, eConsults, and eOrders to… Read More
WELL achieved record quarterly revenues of $170.9 million and record Adjusted EBITDA(1) of $27.8 million in Q2-2023. This was WELL’s 18th consecutive quarter of record revenue performance. WELL surpassed a total of… Read More
PharmAla Continues to Support Clinical Trials as the Foremost Supplier of GMP LaNeo MDMA in Australia. VANCOUVER, BC — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF),… Read More
Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024 Seasoned life sciences executive, Mike Kelly, appointed President & CEO… Read More
Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder with topline data expected in late November to mid-December Continued progress across all XEN1101 Phase 3 epilepsy… Read More
